Novo Nordisk: acquisition of treatment for hypertension

(CercleFinance.com) - Novo Nordisk announces the acquisition of Ocedurenone for the treatment of uncontrolled hypertension from KBP Biosciences.

The transaction is worth up to US$1.3bn.

Ocedurenone is an oral, small-molecule, non-steroidal mineral-ocorticoid receptor antagonist (nsMRA) currently being investigated in the CLARION-CKD phase 3 trial in patients with uncontrolled hypertension and advanced chronic kidney disease (CKD).

Uncontrolled hypertension occurs when a person's blood pressure remains high despite taking two or more blood pressure-lowering treatments.

With its expected benefit-risk profile, okedurenone has best-in-class potential in the treatment of uncontrolled hypertension and could help address a major unmet medical need in people living with cardiovascular disease and chronic kidney disease, said Martin Holst Lange, Executive Vice President and Head of Development at Novo Nordisk.


Copyright (c) 2023 CercleFinance.com. All rights reserved.